Experimental vaccine aims to boost immune attack on glioblastoma
NCT ID NCT07347210
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding a cancer vaccine (UCPVax) with or without an immunotherapy drug (pembrolizumab) to standard treatment can help people with a newly diagnosed, aggressive type of glioblastoma live longer. About 98 adults whose tumors have a specific genetic marker (unmethylated MGMT) will be randomly assigned to one of three groups. The study will measure how many are alive after 18 months and look for immune changes in the tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UCPVax (a cancer vaccine targeting telomerase) with or without pembrolizumab (an immunotherapy drug), plus temozolomide (chemotherapy) and optional tumor-treating fields
What this could lead to
If successful, this combination could extend survival for people with a hard-to-treat brain cancer (glioblastoma) by helping the immune system fight the tumor more effectively.
What could go wrong
This is an early phase 2 trial with only 98 participants, so results may not apply to all patients. The vaccine and immunotherapy can cause immune-related side effects, and the overall benefit is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU La Timone
Marseille, France
Contact
Contact
-
CHU de Besançon
Besançon, France
Contact
Contact
-
Centre Georges François Leclerc
Dijon, France
Contact
Contact
-
Hôpital Saint-Louis - APHP
Paris, France
Contact
Contact